Lapatinib for treatment of advanced or metastasized breast cancer: systematic review.
about
Methodological quality of systematic reviews and clinical trials on women's health published in a Brazilian evidence-based health journalLapatinib plus chemotherapy or endocrine therapy (CET) versus CET alone in the treatment of HER-2-overexpressing locally advanced or metastatic breast cancer: systematic review and meta-analysis.
P2860
Lapatinib for treatment of advanced or metastasized breast cancer: systematic review.
description
2009 nî lūn-bûn
@nan
2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Lapatinib for treatment of advanced or metastasized breast cancer: systematic review.
@ast
Lapatinib for treatment of advanced or metastasized breast cancer: systematic review.
@en
Lapatinib for treatment of advanced or metastasized breast cancer: systematic review.
@nl
type
label
Lapatinib for treatment of advanced or metastasized breast cancer: systematic review.
@ast
Lapatinib for treatment of advanced or metastasized breast cancer: systematic review.
@en
Lapatinib for treatment of advanced or metastasized breast cancer: systematic review.
@nl
prefLabel
Lapatinib for treatment of advanced or metastasized breast cancer: systematic review.
@ast
Lapatinib for treatment of advanced or metastasized breast cancer: systematic review.
@en
Lapatinib for treatment of advanced or metastasized breast cancer: systematic review.
@nl
P2860
P1476
Lapatinib for treatment of advanced or metastasized breast cancer: systematic review.
@en
P2093
Marcos Bosi Ferraz
Rachel Riera
P2860
P304
P356
10.1590/S1516-31802009000500009
P577
2009-09-01T00:00:00Z